Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May;40(5):2549-2555.
doi: 10.1007/s12325-023-02491-4. Epub 2023 Apr 1.

Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis"

Jonathan Marshall  1 , Akanksha Sharma  2 , Patrick Darken  3 , Mario Ouwens  4 , Barinder Singh  2 , Deniz Tansey-Dwyer  5
Affiliations
Comment

Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis"

Jonathan Marshall et al. Adv Ther. 2023 May.
No abstract available

Keywords: COPD; Indirect treatment comparison; Network meta-analysis; Triple therapy.

PubMed Disclaimer

Conflict of interest statement

Jonathan Marshall, Patrick Darken, Mario Ouwens, and Deniz Tansey-Dwyer are employees of AstraZeneca and hold stock and/or stock options in the company. Akanksha Sharma and Barinder Singh are employees of Pharmacoevidence Pvt. Ltd.

Figures

Fig. 1
Fig. 1
Replotted network of evidence of Ismaila et al. informing annualized moderate and severe exacerbation analyses. Adapted from Supplementary Figure S3 of Ismaila et al.’s NMA [1], licensed under CC BY-NC 4.0 (https://creativecommons.org/licenses/by-nc/4.0/). Studies/treatments that could not be linked to the network have been removed (Siler 2016 [25] [SAL/FP 50/250 and UMEC 62.5 + SAL/FP 50/250] and Sousa 2016 [26] [ICS/LABA and UMEC 62.5 + ICS/LABA]). Treatment boxes have been rearranged so that the network connections are clearer. Study labels have been adapted to focus on the connection between FULFIL and KRONOS, which hinges on a single common treatment comparator (BUD/FOR 400/12). BDP beclomethasone dipropionate, BUD budesonide, FF fluticasone furoate, FOR formoterol, FP fluticasone propionate, GLY glycopyrronium bromide, ICS inhaled corticosteroid, IND indacaterol, LABA long-acting β2-agonist, NMA network meta-analysis, SAL salmeterol, TIO tiotropium, UMEC umeclidinium, VI vilanterol
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Ismaila AS, Haeussler K, Czira A, et al. Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis. Adv Ther. 2022;39:3957–3978. doi: 10.1007/s12325-022-02231-0. - DOI - PMC - PubMed
    1. Chaimani A, Caldwell DM, Li T, Higgins JPT, Salanti G. Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, et al (editors). Cochrane handbook for systematic reviews of interventions. Version 6.3 (updated February 2022). Cochrane; 2022. https://training.cochrane.org/handbook.
    1. Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17:157–173. doi: 10.1016/j.jval.2014.01.004. - DOI - PubMed
    1. Deeks JJ, Higgins JPT, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, et al (editors). Cochrane handbook for systematic reviews of interventions. Version 6.3 (updated February 2022). Cochrane; 2022. Available from https://training.cochrane.org/handbook.
    1. Tonin FS, Rotta I, Mendes AM, Pontarolo R. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada) 2017;15:943. doi: 10.18549/PharmPract.2017.01.943. - DOI - PMC - PubMed

MeSH terms